Frontlight ResearchEarly access
What researchers published on Chronic myeloid leukaemia
8,372 papers, newest first.
Showing 20 of 328
Trial resultPopulation Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.Clinical pharmacokinetics
In plain wordsRead moreRead the paper on PubMedRandomised trialFive-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.Leukemia
In plain wordsRead moreRead the paper on PubMedTrial resultAsciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.Leukemia
In plain wordsRead moreRead the paper on PubMedRandomised trialAsciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.Cancer medicine
In plain wordsRead moreRead the paper on PubMedTrial resultEarly predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.Blood advances
In plain wordsRead moreRead the paper on PubMedTrial resultEffects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia.Clinical and translational science
In plain wordsRead moreRead the paper on PubMedRandomised trialFinal results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.The Lancet. Haematology
In plain wordsRead moreRead the paper on PubMedTrial resultASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.Leukemia
In plain wordsRead moreRead the paper on PubMedRandomised trialClinical pharmacokinetic characteristics and the food effect of radotinib.Investigational new drugs
In plain wordsRead moreRead the paper on PubMedTrial resultOutcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.Clinical lymphoma, myeloma & leukemia
In plain wordsRead moreRead the paper on PubMedTrial resultOne-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.Annals of hematology
In plain wordsRead moreRead the paper on PubMedRandomised trialTreatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.Leukemia
In plain wordsRead moreRead the paper on PubMedRandomised trialRandomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).Leukemia
In plain wordsRead moreRead the paper on PubMedTrial resultThe PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.British journal of haematology
In plain wordsRead moreRead the paper on PubMedTrial resultReal-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.Cancer
In plain wordsRead moreRead the paper on PubMedRandomised trialAsciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.Blood
In plain wordsRead moreRead the paper on PubMedRandomised trialNilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.Leukemia
In plain wordsRead moreRead the paper on PubMedTrial resultExposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.Cancer chemotherapy and pharmacology
Trial resultTreatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.Hematological oncology
Trial resultSensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.European journal of haematology